Exploring immune cells in cancer patients through blood sampling

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the presence of tumor-antigen specific immune cells in patients with invasive tumors, where the immune system's role is suspected. Participants will undergo lymphapheresis to collect blood samples for analysis. The study focuses on patients who are being treated with immune-modulating therapies or have suspected immune-mediated responses. The goal is to better understand the immune response in cancer patients and its implications for treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient aged 18 or over,
2. Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol,
3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters,
4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),
5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement,
6. Total circulating lymphocytes\> 1000 / mm3,
7. Availability of DNA and RNA from the tumor,
8. Information to the patient and signature of informed consent or his legal representative,
9. Affiliated with a social security scheme or such a scheme.

Exclusion Criteria:

1. Inability to undergo study follow-up for geographical, social or psychological reasons,
2. Infection with HIV or hepatitis B or C viruses,
3. Patients on high dose corticosteroid treatment (\> 1 mg / kg continuously),
4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease),
5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.),
6. Pregnant patient or of childbearing age without effective contraception,
7. Persons deprived of their liberty, under guardianship or legal protection.

Where it's running

• Institut Curie
  Paris, France Recruiting
• Institut Curie
  Saint-Cloud, France Recruiting

Study contacts

• Study coordinator: Cyrine EZZILI, PhD
• Email: cyrine.ezzili@curie.fr
• Phone: 0033147111657

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using enteral (tube) feeding as recommended for adults with cancer.

  This project will see how well enteral (tube) feeding recommendations are followed by adults hospitalized for cancer who need enteral nutrition.

  Recruiting Institut Curie · Paris · NCT07571564

• Home-capillary blood sampling to monitor CDK4/6 inhibitors in breast cancer

  This study tests whether fingertip capillary samples collected at home can reliably measure drug levels for breast cancer patients treated with ribociclib, abemaciclib, or palbociclib, compared with standard venous draws.

  Recruiting Institut Curie · Paris and 1 other locations · NCT07491380

• Screening and care for fear that breast or lung cancer will come back or get worse at Institut Curie

  This project will test brief screening methods to find people at Institut Curie with severe fear that their breast or lung cancer will come back or progress so they can get appropriate help.

  Recruiting Institut Curie · Paris · NCT07357311

• Tucatinib plus trastuzumab for HER3-mutant, HER2-not amplified metastatic breast cancer

  This trial will test whether combining tucatinib and trastuzumab helps people with metastatic or unresectable breast cancer whose tumors are HER2-negative but carry activating ERBB3 (HER3) mutations.

  Recruiting Phase 2 Institut Curie · Bordeaux and 8 other locations · NCT07193394

• Skin reactions from chest implantable port dressings

  This study will see how often dressings on chest implantable ports cause skin reactions in adults starting first-line chemotherapy.

  Recruiting Institut Curie · Paris and 2 other locations · NCT07158879

• PET-FAPI imaging to find pancreatic cancer earlier

  This will try a PET scan using a FAPI tracer to find early or returning pancreatic cancer in adults with recently diagnosed non‑metastatic PDAC who are enrolled in the HoMING cohort.

  Recruiting Phase 2 Institut Curie · Saint-Cloud · NCT06659705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.